title: [Clinically relevant pharmacokinetic drug interactions in the intensive care unit: an overview].
abstract: Critically ill patients in the intensive care unit (ICU) are predisposed to pharmacokinetic drug interactions because of the complexity of the drug regimens received in the intensive care setting. Drugs may affect the absorption, distribution, metabolism and/or elimination of an object drug and consequently alter the intended pharmacologic response and potentially lead to an adverse event. The paper presents an overview of pharmacokinetic drug-drug interactions which can occur with commonly used drugs in the ICU and outlines the underlying types and mechanisms.
authors.affiliation: HSK, Dr. Horst Schmidt Kliniken GmbH, Ludwig-Erhard-Str. 100, 65199, Wiesbaden, Deutschland. wolfgang.kaemmerer@hsk-wiesbaden.de
authors.forename: W
authors.initials: W
authors.lastname: Kämmerer
mesh_terms: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000819:agonists / Q000037:antagonists & inhibitors / Q000502:physiology; D001711:Biotransformation / Q000502:physiology; D003422:Critical Care; D065607:Cytochrome P-450 Enzyme Inhibitors; D003577:Cytochrome P-450 Enzyme System / Q000502:physiology; D004347:Drug Interactions; D004359:Drug Therapy, Combination / Q000009:adverse effects; D004790:Enzyme Induction / Q000502:physiology; D005260:Female; D006801:Humans; D050216:Metabolic Detoxication, Phase I / Q000502:physiology; D010599:Pharmacokinetics; D011247:Pregnancy; D011248:Pregnancy Complications / Q000097:blood / Q000188:drug therapy*
chemical_list: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D065607:Cytochrome P-450 Enzyme Inhibitors; D003577:Cytochrome P-450 Enzyme System